Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for ARWR

Stock NameArrowhead Pharmaceuticals Inc
TickerARWR(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS04280A1007
LEI549300O3CSB8T7OZ3D66

Show aggregate ARWR holdings

News associated with ARWR

7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?
(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impulses." - 2025-09-15 03:55:16
Mitsubishi UFJ Asset Management Co. Ltd. Has $184,000 Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 9.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,476 shares of the biotechnology company’s stock after purchasing an additional […] - 2025-08-15 05:44:58
XTX Topco Ltd Buys New Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
XTX Topco Ltd bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) in the 1st quarter, Holdings Channel.com reports. The fund bought 10,421 shares of the biotechnology company’s stock, valued at approximately $133,000. Several other institutional investors and hedge funds have also recently bought and sold shares of ARWR. GAMMA […] - 2025-08-15 05:02:51
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Mutual of America Capital Management LLC
Mutual of America Capital Management LLC trimmed its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 72.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,363 shares of the biotechnology company’s stock after selling 47,305 shares during the period. Mutual of America Capital Management […] - 2025-08-14 05:23:02
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at B. Riley
B. Riley upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) to a strong-buy rating in a report issued on Monday,Zacks.com reports. B. Riley also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at $0.69 EPS, FY2025 earnings at $0.82 EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($0.75) EPS, FY2028 earnings at ($2.09) […] - 2025-08-14 02:42:49
Bullish Two Hundred Day Moving Average Cross - ARWR
In trading on Tuesday, shares of Arrowhead Pharmaceuticals Inc (Symbol: ARWR) crossed above their 200 day moving average of $17.48, changing hands as high as $18.13 per share. Arrowhead Pharmaceuticals Inc shares are currently trading up about 3.6% on the day. The chart below - 2025-08-12 12:55:22
Universal Beteiligungs und Servicegesellschaft mbH Makes New $174,000 Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 13,622 shares of the biotechnology company’s stock, valued at approximately $174,000. Several other institutional […] - 2025-08-06 04:31:05
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Strong-Buy at TD Cowen
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) was upgraded by analysts at TD Cowen to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports. ARWR has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report […] - 2025-07-30 02:20:43
Mutual of America Capital Management LLC Trims Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Mutual of America Capital Management LLC decreased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 72.0% during the 1st quarter, Holdings Channel.com reports. The firm owned 18,363 shares of the biotechnology company’s stock after selling 47,305 shares during the period. Mutual of America Capital Management LLC’s holdings in Arrowhead Pharmaceuticals […] - 2025-07-24 04:36:58
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Position Lowered by Bank of New York Mellon Corp
Bank of New York Mellon Corp lessened its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 6.5% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 776,039 shares of the biotechnology company’s stock after selling 54,019 shares during the period. Bank of New York […] - 2025-07-22 06:34:43
Bullish Two Hundred Day Moving Average Cross - ARWR
In trading on Wednesday, shares of Arrowhead Pharmaceuticals Inc (Symbol: ARWR) crossed above their 200 day moving average of $17.82, changing hands as high as $18.37 per share. Arrowhead Pharmaceuticals Inc shares are currently trading up about 3.2% on the day. The chart belo - 2025-07-09 12:39:36
Oregon Public Employees Retirement Fund Boosts Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Oregon Public Employees Retirement Fund lifted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 14.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 28,884 shares of the biotechnology company’s stock after buying an additional 3,546 shares during the quarter. Oregon Public […] - 2025-07-09 05:34:54
New York State Teachers Retirement System Buys 9,593 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
New York State Teachers Retirement System lifted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 6.9% in the first quarter, HoldingsChannel.com reports. The firm owned 148,376 shares of the biotechnology company’s stock after purchasing an additional 9,593 shares during the period. New York State Teachers Retirement System’s holdings in Arrowhead […] - 2025-07-09 04:56:25
How The Parts Add Up: VIOO Headed For $118
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-23 08:46:06
Assenagon Asset Management S.A. Has $289,000 Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Assenagon Asset Management S.A. trimmed its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 57.2% during the first quarter, HoldingsChannel reports. The institutional investor owned 22,701 shares of the biotechnology company’s stock after selling 30,312 shares during the period. Assenagon Asset Management S.A.’s holdings in Arrowhead Pharmaceuticals were worth $289,000 at […] - 2025-06-20 04:52:52
Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $43.71
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year […] - 2025-06-13 02:55:10
California State Teachers Retirement System Lowers Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
California State Teachers Retirement System trimmed its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 1.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 105,154 shares of the biotechnology company’s stock after selling 1,139 shares during the quarter. California State Teachers Retirement System’s holdings in Arrowhead Pharmaceuticals were worth $1,977,000 at […] - 2025-06-08 05:49:07
Mackenzie Financial Corp Buys New Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Mackenzie Financial Corp acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 7,299 shares of the biotechnology company’s stock, valued at approximately $137,000. Other large investors also recently modified their holdings of the company. Raymond James Financial Inc. bought a new […] - 2025-06-06 04:49:00
Squarepoint Ops LLC Has $1.62 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Squarepoint Ops LLC reduced its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 55.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 86,044 shares of the biotechnology company’s stock after selling 107,750 shares during the quarter. Squarepoint Ops […] - 2025-05-30 06:08:58
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Tidal Investments LLC
Tidal Investments LLC lowered its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 4.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,249 shares of the biotechnology company’s stock after selling 1,062 shares during the period. Tidal Investments LLC’s holdings in Arrowhead Pharmaceuticals were […] - 2025-05-30 05:25:01
Millennium Management LLC Acquires 268,946 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Millennium Management LLC lifted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 41.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 914,550 shares of the biotechnology company’s stock after acquiring an additional 268,946 shares during the period. Millennium […] - 2025-05-22 05:01:01
HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $80.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 422.53% from the company’s current price. […] - 2025-05-22 02:58:43
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Raised to “Hold” at StockNews.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday. Several other equities analysts have also recently commented on the stock. B. Riley restated a “buy” rating and set a $38.00 price target (down from $51.00) on […] - 2025-05-16 05:46:55
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Comerica Bank
Comerica Bank reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 5.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,921 shares of the biotechnology company’s stock after selling 2,259 shares during the quarter. Comerica Bank’s holdings […] - 2025-05-15 05:08:52
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $60.00 price objective on the biotechnology company’s stock. Several other research firms have also recently commented on ARWR. B. Riley reissued a “buy” rating and set a $38.00 […] - 2025-05-14 04:58:52
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Cut to $17.00 by Analysts at Citigroup
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price reduced by Citigroup from $21.00 to $17.00 in a research report released on Tuesday morning,Benzinga reports. Citigroup currently has a neutral rating on the biotechnology company’s stock. Several other equities research analysts also recently commented on the company. B. Riley restated a “buy” rating and […] - 2025-05-14 04:58:48
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up After Strong Earnings
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $13.97, but opened at $15.75. Arrowhead Pharmaceuticals shares last traded at $15.56, with a volume of 844,732 shares trading hands. The biotechnology company reported $2.75 […] - 2025-05-14 02:40:47
Northern Trust Corp Purchases 151,654 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Northern Trust Corp raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 11.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,484,419 shares of the biotechnology company’s stock after buying an additional 151,654 shares during the period. Northern Trust Corp’s holdings in Arrowhead Pharmaceuticals were worth $27,907,000 at the end […] - 2025-05-12 05:36:56
Voya Investment Management LLC Sells 246,573 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Voya Investment Management LLC trimmed its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 82.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 53,793 shares of the biotechnology company’s stock after selling 246,573 shares during the period. Voya Investment Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,011,000 as of its […] - 2025-05-07 05:57:00
Bank of Montreal Can Boosts Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Bank of Montreal Can grew its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 13.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,018 shares of the biotechnology company’s stock after purchasing an additional 1,759 shares […] - 2025-04-25 04:36:52

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ARWR holdings

DateNumber of ARWR Shares HeldBase Market Value of ARWR SharesLocal Market Value of ARWR SharesChange in ARWR Shares HeldChange in ARWR Base ValueCurrent Price per ARWR Share HeldPrevious Price per ARWR Share Held
2025-09-26 (Friday)40,657USD 1,333,550USD 1,333,550
2025-09-25 (Thursday)40,657USD 1,287,201ARWR holding decreased by -47568USD 1,287,2010USD -47,568 USD 31.66 USD 32.83
2025-09-24 (Wednesday)40,657USD 1,334,769USD 1,334,769
2025-09-17 (Wednesday)40,395USD 1,176,706ARWR holding decreased by -11715USD 1,176,7060USD -11,715 USD 29.13 USD 29.42
2025-09-16 (Tuesday)40,395USD 1,188,421USD 1,188,421
2025-09-12 (Friday)40,133USD 1,192,753USD 1,192,753
2025-09-11 (Thursday)40,133USD 1,192,753USD 1,192,753
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ARWR by Blackrock for IE00B3VWM098

Show aggregate share trades of ARWR

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-08-21SELL-188 20.750* 17.15 Profit of 3,224 on sale
2025-07-31BUY564 15.800* 17.14
2025-06-30SELL-376 15.800* 17.18 Profit of 6,459 on sale
2025-06-25SELL-188 15.660* 17.21 Profit of 3,235 on sale
2025-06-20SELL-376 15.320* 17.24 Profit of 6,482 on sale
2025-05-30BUY5,901 16.070* 17.36
2025-05-23BUY167 15.130* 17.43
2025-05-19SELL-167 15.740* 17.49 Profit of 2,921 on sale
2025-05-15SELL-504 15.340* 17.53 Profit of 8,833 on sale
2025-05-12SELL-168 13.970* 17.60 Profit of 2,957 on sale
2025-05-09SELL-168 13.030* 17.64 Profit of 2,964 on sale
2025-04-30SELL-168 13.890* 17.91 Profit of 3,009 on sale
2025-04-24SELL-336 13.340* 18.10 Profit of 6,080 on sale
2025-04-17SELL-168 11.240* 18.42 Profit of 3,095 on sale
2025-04-15SELL-504 12.870* 18.56 Profit of 9,353 on sale
2025-04-14SELL-504 12.340* 18.63 Profit of 9,388 on sale
2025-04-09SELL-672 11.800* 18.87 Profit of 12,679 on sale
2025-04-07SELL-1,176 10.250* 19.07 Profit of 22,427 on sale
2025-04-04SELL-1,680 10.680* 19.17 Profit of 32,205 on sale
2025-03-31BUY168 12.740* 19.41
2025-03-19SELL-336 15.470* 19.93 Profit of 6,696 on sale
2025-03-14SELL-1,008 15.360* 20.12 Profit of 20,282 on sale
2025-03-13SELL-336 15.070* 20.19 Profit of 6,785 on sale
2025-03-12SELL-5,712 15.770* 20.26 Profit of 115,708 on sale
2025-03-07SELL-336 16.970* 20.46 Profit of 6,875 on sale
2025-03-06SELL-504 17.670* 20.50 Profit of 10,334 on sale
2025-03-03SELL-168 17.710* 20.66 Profit of 3,470 on sale
2025-02-28BUY9,286 18.910* 20.68
2025-02-26SELL-142 19.230* 20.74 Profit of 2,945 on sale
2025-02-25SELL-426 19.530* 20.76 Profit of 8,843 on sale
2025-02-18BUY710 20.440* 20.81
2025-02-13BUY142 19.110* 20.88
2025-02-12BUY142 18.570* 20.92
2025-02-11BUY426 18.890* 20.97
2025-02-06BUY1,278 20.480* 21.02
2025-01-27BUY142 20.250* 21.26
2024-12-30BUY710 18.610* 21.40
2024-12-06BUY568 23.610* 21.18
2024-12-05BUY142 22.300* 21.14
2024-12-04BUY710 23.110* 21.07
2024-11-29BUY710 26.030* 20.46
2024-11-27BUY564 26.150* 19.96
2024-11-26BUY141 21.050* 19.91
2024-11-21BUY705 18.280* 20.13
2024-11-20BUY423 18.710* 20.21
2024-11-18BUY1,692 19.020* 20.39
2024-11-12BUY1,128 21.510* 20.31
2024-11-08BUY705 21.890* 20.20
2024-11-07BUY2,115 21.390* 20.11
2024-11-06BUY282 21.340* 20.00
2024-10-31BUY141 19.230* 20.09
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ARWR

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19376,4070674,97955.8%
2025-09-18524,0540960,09754.6%
2025-09-17296,15232760,75538.9%
2025-09-16300,0510670,15044.8%
2025-09-15427,6422661,049,25840.8%
2025-09-12668,15901,301,34951.3%
2025-09-11670,36901,229,35354.5%
2025-09-10529,9446,3751,121,51447.3%
2025-09-09454,5840871,62652.2%
2025-09-08476,6668581,027,43646.4%
2025-09-05686,6872101,180,73158.2%
2025-09-04742,9514,9691,545,17548.1%
2025-09-031,333,9501,8132,542,56652.5%
2025-09-021,629,5513413,050,13453.4%
2025-08-29440,04388939,59446.8%
2025-08-28600,9446671,089,85455.1%
2025-08-27476,74201,080,15844.1%
2025-08-26255,0966,673497,97251.2%
2025-08-25325,4070737,03244.2%
2025-08-22390,84601,019,88838.3%
2025-08-21512,9030960,94353.4%
2025-08-20491,1910810,62960.6%
2025-08-19285,275103713,72040.0%
2025-08-18453,7195992,73445.7%
2025-08-15649,0823002,430,37326.7%
2025-08-14709,6461,2251,999,53635.5%
2025-08-13522,7752,995993,88752.6%
2025-08-12323,8690582,55955.6%
2025-08-11529,7050829,91463.8%
2025-08-08493,63801,028,51048.0%
2025-08-07425,1907,755631,00267.4%
2025-08-06518,06552684,20175.7%
2025-08-05259,72526425,96761.0%
2025-08-04256,3160388,35966.0%
2025-08-01392,30983526,39174.5%
2025-07-31246,8620395,65962.4%
2025-07-30417,967775558,89174.8%
2025-07-29354,962311535,84766.2%
2025-07-28391,5565,215548,95471.3%
2025-07-25511,6120601,83285.0%
2025-07-24809,7034721,100,53973.6%
2025-07-231,142,6511,8771,501,51076.1%
2025-07-22543,61537,241944,11457.6%
2025-07-211,927,85740,0893,233,11859.6%
2025-07-18599,8911,370939,77963.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.